Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis.
Eustachio NettisLucia MasciopintoElisabetta Di LeoNicola De CandiaMarcello AlbanesiDanilo Di BonaNicola QuarantaLuigi Macchia
Published in: Clinical and molecular allergy : CMA (2021)
Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.